Tasso, Inc. Joint Venture Receives Controlled Medical Device Approval in Japan for Novel Self-Administered Blood Collection Device
Certification clears path in Japan for wider access to preventive medicine, telemedicine, and reduced provider burden
SEATTLE – September 9, 2025 – Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that the TS Blood Collection Kit, a product of Tasso-SNBL, Ltd., received certification as a controlled medical device under Japan’s Pharmaceuticals and Medical Devices Act. This certification was conducted by a third-party certification body registered with the Ministry of Health, Labour and Welfare (MHLW) and confirms the product’s safety, performance, and quality control system comply with relevant regulations.
The TS Blood Collection Kit integrates Tasso’s signature lancet technology with a compatible collection reservoir to deliver a virtually painless, self-administered solution for collecting high-quality blood samples. Designed for use anywhere, including at home, the kit minimizes patient discomfort while ensuring reliable results for healthcare providers.
With Japan facing an aging population and ongoing healthcare workforce shortages, this certification enables new ways to close critical gaps in access. By allowing patients to self-collect high-quality blood samples at home, the technology could support earlier detection, continuity of care through telemedicine, and a reduced reliance on in-clinic blood draws, thus easing the strain on Japan’s healthcare workers and giving patients more access to care.
Tasso-SNBL, Ltd. was established in March 2025 as a joint venture between Tasso and Shin Nippon Biomedical Laboratories, Ltd. The company holds the exclusive rights to import and distribute Tasso capillary blood self-collection devices in Japan.
“This certification marks an important step for our joint venture with SNBL and for patients across Japan,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “As healthcare needs continue to evolve worldwide, Tasso remains committed to delivering patient-centric innovations that expand access, improve comfort, and reduce the burden on healthcare systems.”
To learn more about Tasso’s patient-centric blood collection solutions, visit www.tassoinc.com.
About Tasso
Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.
Media Contacts
Tasso Media Relations
Tasso-SNBL, Ltd.